Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer of the Liver Clear all
Terminated Phase 1Phase 2 Interventional Results available

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 10, 2026, 7:09 AM EDT
Suspended Not applicable Interventional

Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation

NCT02935478
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Hepatocellular Carcinoma, HCC, Hepatitis C, Cirrhosis
Interventions
Embospheres Microspheres
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

NCT02988440
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
PDR001, Sorafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

NCT00004074
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
Interventions
recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

NCT00666978
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
smoking cessation intervention, bupropion hydrochloride, gene expression analysis, polymerase chain reaction, counseling intervention, educational intervention, psychosocial assessment and care
Behavioral · Drug · Genetic + 2 more
Lead sponsor
Lisa Sanderson Cox, PhD
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 10, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT06995898
View directory record Official record
Conditions
Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Biospecimen Collection, Device Usage, Electronic Health Record Review, Multi-Cancer Detection Test, Questionnaire Administration
Procedure · Device · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 75 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
45
States / cities
Pleasanton, California • Cheyenne Wells, Colorado • Denver, Colorado + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Not applicable Interventional

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

NCT03889093
View directory record Official record
Conditions
Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Interventions
Yttrium-90
Other
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 10, 2026, 7:09 AM EDT
Completed No phase listed Observational

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

NCT00132704
View directory record Official record
Conditions
Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions
Ionizing radiation (IR) therapy, Ionizing radiation (IR)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 10, 2026, 7:09 AM EDT
Not listed Phase 2 Interventional

A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.

NCT00152087
View directory record Official record
Conditions
Liver Cancer
Interventions
Brachytherapy
Device
Lead sponsor
St. Joseph's Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2005 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002716
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, leucovorin calcium, laparotomy, conventional surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
11
States / cities
Cedar Rapids, Iowa • Des Moines, Iowa • Papillion, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

NCT01337492
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Nexavar
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 10, 2026, 7:09 AM EDT
Recruiting Phase 2 Interventional

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

NCT05620771
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
7
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

NCT00030563
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, adjuvant therapy, conventional surgery, radiofrequency ablation
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

NCT02042443
View directory record Official record
Conditions
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
295
States / cities
Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

NCT06812780
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AZD2389
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
5
States / cities
Chandler, Arizona • Rialto, California • Miami Lakes, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT00862082
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib
Drug
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 1Phase 2 Interventional

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

NCT03223779
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102, Photon SBRT
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262
View directory record Official record
Conditions
Primary Malignant Liver Neoplasm
Interventions
Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres, Technetium 99mTc albumin aggregated (99mTc-MAA), Single-photon emission computerized tomography (SPECT) scan
Procedure · Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Extracellular RNA Markers of Liver Disease and Cancer

NCT02908048
View directory record Official record
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer, Cirrhosis, Liver Diseases
Interventions
Blood samples
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Enrolling by invitation Phase 4 Interventional

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

NCT02081755
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Everolimus, Tacrolimus, Myfortic, CellCept, Imuran
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

NCT00788125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 1Phase 2 Interventional

A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care

NCT00081900
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
DENSPM )
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 1 Interventional

Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer

NCT00072098
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
adenovirus vector, interleukin-12 gene
Biological
Lead sponsor
Max Sung
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 10, 2026, 7:09 AM EDT